Declaration of competing financial interests
From the following article:
Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers
Mark R. Trusheim, Ernst R. Berndt & Frank L. Douglas
Nature Reviews Drug Discovery 6, 287-293 (April 2007)
doi:10.1038/nrd2251
Declaration: This research has been supported by the MIT Center for Biomedical Innovation, which receives some of its funding from various biopharmaceutical industry sources. Through Co-Bio Consulting LLC, M.R.T. advises companies, universities and government agencies on biotechnology business and economic development strategies. E.R.B. has consulted for various biotechnology and pharmaceutical companies, federal government agencies, and health maintenance organizations. F.L.D. is Chairman of the Board of Directors of Alantos Pharmaceuticals and Member of the Board of Directors of Gene Logic and Nitromed. He is also scientific advisor to the Bayer HealthCare Group. M.R.T., E.R.B. and F.L.D. are also each uncompensated Special Government Employees at the Office of the Commissioner, U.S. Food and Drug Administration.
